ALL: Clinical Trials

5 trials for ALL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 5
Phase 14Terminated 4

Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL
Phase 1 / Phase 2TerminatedAO GENERIUM142020-10-152026-09-21
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OTS167IV - AML, Advanced MDS
Phase 1 / Phase 2TerminatedOncoTherapy Science, Inc.322016-04-012021-11-24
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University42012-03-012025-05-04
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL
Phase 1 / Phase 2TerminatedDuke University152007-07-012013-11-25
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma
Phase 1 / Phase 2TerminatedAbramson Cancer Center at Penn Medicine42007-01-012025-11-05

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Leukemia (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Burkitt Lymphoma (1)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)

Broader conditions

Hemic and Lymphatic Diseases (4)  ·  Hematologic Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia (2)  ·  Leukemia, Lymphoid (2)  ·  Leukemia, Myeloid (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Chronic Disease (1)  ·  DNA Virus Infections (1)  ·  Disease Attributes (1)

Interventions

Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Etoposide (1)  ·  Mycophenolic Acid (1)  ·  Radiotherapy (1)  ·  Sirolimus (1)  ·  Stem Cell Transplantation (1)  ·  Tacrolimus (1)  ·  Whole-Body Irradiation (1)

Sponsors

AO GENERIUM (1)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Duke University (1)  ·  OncoTherapy Science, Inc. (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)

Countries

United States (3)  ·  Russia (1)

Top investigators

Dolores Grosso, DNP, CRNP (1)  ·  Mitchell Horwitz, MD (1)  ·  Neal Flomenberg, MD (1)  ·  Oksana A. Markova, MD (1)  ·  Olatoyosi Odenike, MBBS (1)  ·  Selina Luger, MD (1)

Results publications

PMID 35622074